Tumor Progression, Parallel Mechanisms and Therapeutic Targets
Cancers · 06.08.2026 · 18 (15) · 2518
DOI: 10.3390/cancers18152518 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.08.2026. Verfasst von Leif Håkansson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Tumorimmunology, Department of Oncology, University Hospital of Linkoping, 581 85 Linkoping, Sweden. Die Arbeit nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer progression is driven by early dysregulation of the immune system and tumor-intrinsic mechanisms. Hypoxia, lactate accumulation and IL-6 signaling induce highly overlapping tumor-promoting effects, including angiogenesis, epithelial–mesenchymal transition, metastasis, immune evasion and treatment resistance, suggesting that these pathways interact and amplify one another. This parallel activation complicates therapeutic targeting, as inhibition of one pathway may be compensated for by another. Increased proteolytic activity emerges early during tumor development and profoundly alters immune regulation. We recently identified a protease-generated albumin fragment, the IL-6-inducing factor (IL-6IF), which triggers pathological IL-6 production. IL-6 in turn enhances both HIF-1α expression and nuclear translocation, promotes glycolysis and lactate production, and forms positive feedback loops with STAT3 and multiple signaling pathways. Together, these mechanisms integrate into a self-sustaining IL-6/HIF-1α/STAT3 axis that drives tumor progression and suppresses anti-tumor immunity. The strong overlap among IL-6, its enhancing loops and hypoxia-driven mechanisms highlights IL-6 as a central regulator of metabolic and immunological reprogramming in cancer. However, a broad IL-6 blockade can impair physiological immune function. Selective inhibition of IL-6IF offers a novel strategy to prevent pathological IL-6 production while preserving physiological IL-6-dependent immune function required for effective tumor control. Reducing pathologically enhanced IL-6 synthesis by targeting IL-6IF, therefore, might represent a potential therapeutic approach to disrupt multiple tumor-promoting pathways simultaneously and may thereby improve responsiveness to cancer immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Tumorimmunology, Department of Oncology, University Hospital of Linkoping, 581 85 Linkoping, Sweden.
- Therim Diagnostica AB, 236 37 Höllviken, Sweden.
- Department of Clinical Sciences Malmö, Lund University, 205 02 Malmö, Sweden.
- Department of Oncology, Uppsala University Hospital, 751 85 Uppsala, Sweden.
ORCID-Profile: Pontus Dunér
Zitieren
APA
Håkansson, L., Dunér, P., & Håkansson, A. (2026). Tumor Progression, Parallel Mechanisms and Therapeutic Targets. Cancers, 18(15), 2518. https://doi.org/10.3390/cancers18152518
Vancouver
Håkansson L, Dunér P, Håkansson A. Tumor Progression, Parallel Mechanisms and Therapeutic Targets. Cancers. 2026;18(15):2518. doi:10.3390/cancers18152518
BibTeX
@article{Hkansson2026,
author = {Håkansson, Leif and Dunér, Pontus and Håkansson, Annika},
title = {Tumor Progression, Parallel Mechanisms and Therapeutic Targets},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2518},
doi = {10.3390/cancers18152518}
}
EUVIMED